- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02559921
Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.
19. januar 2016 opdateret af: Beijing Chaoyang District Centre for Disease Control and Prevention
This study evaluates the rabies virus neutralizing antibody (RVNA) activities ,safety and tolerability of rhRIG vs. HRIG in combination with rabies vaccine for human use (Vero cells) in healthy adult subjects.The study has 7 groups.Subjects will receive rhRIG(20 IU/kg)only, rhRIG(40 IU/kg)only,HRIG(20 IU/kg)only, rhRIG(20 IU/kg)in combination with rabies vaccine for human use, rhRIG(40 IU/kg)in combination with rabies vaccine for human use,HRIG(20 IU/kg)in combination with rabies vaccine for human use,and placebo in combination with rabies vaccine for human use,respectively.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
300
Fase
- Fase 2
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or female subjects aged at least 18 years but not more than 55 years;
- According to medical history, physical examination and clinical judgment of investigator at enrollment, subjects should have no significant health problems, or their health status or medication treatment remain stable;
- Subjects and their spouses should use adequate contraceptive methods from the screening day to Day 90;
- Male subjects must agree not to donate sperm from the first day of enrollment to Day 90;
- Subjects should sign a written Informed Consent Form;
Exclusion Criteria:
- Previous exposure or immunization histories of rabies (rabies vaccine and/or immunoglobulin);
- According to the clinical judgment of investigator, subjects had clinically significant acute disease or infection, including pyrexia (>37.0℃) within 2 weeks before the initial dose;
- After review of medical history or physical examination results, it is found that subjects have medical histories of abnormalities of heart, liver, kidney, blood, digestive tract, nervous system, spirit and metabolism;
- Subjects are pregnant or plan to become pregnant or are breast-feeding during the study;
- According to the judgment of investigator, subjects have clinically significant immunodeficiency or medical history and/or family history of autoimmune disease;
- According to the judgment of investigator, subjects have known or suspected clinically significant anaphylaxis or hypersensitivity reactions;
- Immunization has been arranged for the subjects within the next 3 months after the initial dose;
- Subjects have used immunosuppressive preparations or other immunomodulating agents for more than 14 days within 6 months before the initial dose of study drug;
- Subjects used hormone agents within 3 days before the initial dose;
- Subjects donated blood or lost a lot of blood within 56 days before the initial dose;
- Subjects donated plasma within 7 days before the initial dose;
- Subjects received transfusion of blood or blood products within 6 months before the initial dose;
- It is suspected that subjects do not follow study procedures;
- Intake of alcohol within 12 hours before the initial dose;
- Subjects smoke more than 20 cigarettes a day;
- Subjects are obviously allergic to antibiotics;
- Any other conditions which may affect trial assessment at the discretion of the investigator;
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: rhRIG(20 IU/kg)only
Subjects received rhRIG(20 IU/kg) on day 0
|
|
Eksperimentel: rhRIG(40 IU/kg)only
Subjects received rhRIG(40 IU/kg) on day 0
|
|
Aktiv komparator: HRIG(20 IU/kg)only
Subjects received HRIG(20 IU/kg)on day 0
|
|
Eksperimentel: rhRIG(20 IU/kg)+ vaccine
Subjects received rhRIG(20 IU/kg)in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
|
|
Eksperimentel: rhRIG(40 IU/kg)+ vaccine
Subjects received rhRIG(40 IU/kg)in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
|
|
Eksperimentel: HRIG(20 IU/kg)+ vaccine
Subjects received HRIG(20 IU/kg)in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
|
|
Placebo komparator: placebo + vaccine
Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Evaluate the detection rate of the rabies virus neutralizing antibody (RVNA) activities of rhRIG vs. HRIG in combination with rabies vaccine for human use (Vero cells) in healthy adult subjects
Tidsramme: 42 days
|
42 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Evaluate the rate of adverse reactions of rhRIG or HRIG in combination with rabies vaccine for human use (Vero cells) in healthy subjects
Tidsramme: 42 days
|
42 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Li L, Li Y, Bai Y, Li G, Zhang J, Yang L, Zhao W, Zhao W, Luo F, Zhao Q, Zhang Z, Liu Y, Li S, Lu Q, Wang H, Zhang J, Zhang Y, Gao J, Shi N. Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase Ⅱb randomized, double-blind, parallel-controlled study. Vaccine. 2022 Oct 6;40(42):6153-6162. doi: 10.1016/j.vaccine.2022.09.022. Epub 2022 Sep 16.
- Zhang J, Shi N, Li G, Li L, Bai Y, Yang L, Zhao W, Gao J, Wei J, Zhao W, Zhai L, Huo P, Ren L, Yu L, Li Y. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218. doi: 10.3390/vaccines10081218.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2014
Primær færdiggørelse (Faktiske)
1. august 2015
Studieafslutning (Faktiske)
1. december 2015
Datoer for studieregistrering
Først indsendt
23. september 2015
Først indsendt, der opfyldte QC-kriterier
24. september 2015
Først opslået (Skøn)
25. september 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
20. januar 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. januar 2016
Sidst verificeret
1. september 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- cycdc2015-3
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med rhRIG(20 IU/kg)
-
Seoul National University HospitalUkendt
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinAfsluttetLymfom, B-celle | Lymfom, Non-Hodgkin | Kronisk lymfatisk leukæmi | Lille lymfatisk lymfomForenede Stater
-
Daiichi Sankyo, Inc.AfsluttetKakeksiForenede Stater, Argentina, Chile, Guatemala, Honduras, Rumænien
-
Aydin Adnan Menderes UniversityAfsluttetPostoperativ kvalme og opkastningKalkun
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human ServicesAfsluttetHIV-infektionerForenede Stater, Zimbabwe, Kenya, Sydafrika
-
International AIDS Vaccine InitiativeBeth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard og andre samarbejdspartnereAfsluttetHIV-infektionerForenede Stater
-
Suzhou Transcenta Therapeutics Co., Ltd.Afsluttet
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRekrutteringAkut lymfatisk leukæmi | Akut lymfoblastisk leukæmi, pædiatrisk | Akut lymfoblastisk leukæmi, i tilbagefald | Akut lymfoblastisk leukæmi Tilbagevendende | Akut lymfatisk leukæmi med mislykket remission | Akut lymfatisk leukæmi, der ikke har opnået remissionForenede Stater
-
Huahui HealthRekrutteringKronisk Hepatitis Delta Virus InfektionKina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdAfsluttetGastrisk/Gastroøsofageal Junction CancerKina